Rigor Reviewed

Rigor-Reviewed Manuscript

Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial.

Name: Αlpha¹ Rigor Record — Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial.
Item: Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial.
Rating: 59
Author: Αlpha¹

Prabhakaran D, Roy A, Chandrasekaran AM, Kondal D, Mukherjee S, Kiru G, Singh K, Salwa H, Sobitharaj EC, Lobo AS, Mahajan G, Mohan B, Khanna A, Malviya A, Patil SG, Abichandani VK, Singh B, Gupta BK, Yellapantula B, Dandge S, Sengupta S, Kumar S, Bardoloi N, Senguttuvan NB, Sahay RK, Patil S, Deora S, Prahalad R, Sarvepalli VP, Gnanaraj JP, Khanna M, Mishra A, Aithal K, Chavda V, Cornelius VR, TOPSPIN Clinical Consortia, Poulter NR

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1.5★ (Critical), 0 critical, 4 high issues for “Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1.5 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
StatisticsStatistic did not reproduce−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 30 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced8 types

Numerical inconsistencies3

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Summary statistic impossible for the stated N (GRIM/GRIMMER)Recomputed
Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns2

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed
Data look implausibly cleanAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted, well-reported randomized clinical trial with a clear scientific premise, rigorous design, and transparent reporting. The main weaknesses are a vague data availability statement and an ethics statement that lacks specific committee names and protocol numbers, plus a few minor copyediting issues.

Both reviewers classified the study as interventional and agreed on all dimensions except the ethics statement's adequacy, which I resolved conservatively to warn. The statistics verification covered only a subset of reported tests; the 2 'inconsistent' entries were not machine-verifiable (likely threshold-only p-values) and do not indicate errors. Citation check found no retracted or missing references.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks. 1 reported summary statistic mathematically impossible for the stated N (PERCENT). 1 printed percentage that does not match its own count.

4 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites global hypertension burden, the rationale for dual combinations, and ethnic differences in BP-lowering efficacy, including the CREOLE trial. It explicitly states the evidence gap for South Asian patients and the rationale for the TOPSPIN trial. Limitations of prior research are addressed by noting the lack of robust data for South Asians and the need for a dedicated trial.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on hypertension burden, ethnic differences in BP response, and the CREOLE trial, and logically motivates the need for South Asian-specific data.

Evidence

direct quote[Introduction, paragraph 1]

“Hypertension affects over 1.3 billion adults worldwide . Elevated BP is the single largest contributor to the global burden of disease and mortality, annually causing 7.8% of the disability-adjusted life years lost and one in six deaths (10.9 million) .”